MaxCyte, Inc. (MXCT) Income Statement
MXCT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsMXCT revenue and net income
Where MXCT's revenue goes
2025Each bar shows an amount and its share of revenue. MXCT kept −135.1% of revenue as net income.
MXCT profit margins
MXCT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −14.5% | −9.3% | +4.8% | +13.5% |
| Gross profit | −15.0% | −11.9% | +2.8% | +12.5% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
MXCT quarterly EPS vs estimates
MaxCyte beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: November 10, 2026 (estimate $-0.08).
MXCT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $33.0M | $38.6M | $41.3M | $44.3M | $33.9M | $26.2M | $21.6M | $16.7M | $14.0M | $12.3M |
| Cost of revenue | $6.2M | $7.1M | $4.7M | $5.1M | $3.6M | $2.8M | $2.5M | $1.8M | $1.5M | $1.3M |
| Gross profit | $26.8M | $31.5M | $36.5M | $39.2M | $30.2M | $23.4M | $19.1M | $14.8M | $12.5M | $11.0M |
| Research & development | $20.8M | $22.2M | $23.8M | $19.5M | $15.4M | $17.7M | $17.6M | $11.2M | $11.3M | $4.7M |
| Sales, general & admin | $47.0M | $56.4M | $57.0M | $44.5M | $31.7M | $15.7M | $13.4M | $12.0M | $10.5M | $9.0M |
| Total operating expenses | $72.1M | $82.7M | $84.8M | $66.5M | $48.4M | $34.5M | $31.5M | $23.3M | $21.8M | $13.7M |
| Operating income | −$45.3M | −$51.2M | −$48.3M | −$27.4M | −$18.2M | −$11.1M | −$12.4M | −$8.4M | −$9.3M | −$2.7M |
| Interest income | $7.3M | $10.1M | $9.5M | $3.9M | $150,800 | $65,900 | $206,100 | $170,300 | — | — |
| Interest expense | — | — | — | $126,900 | $1.0M | $825,600 | $681,100 | $614,600 | $625,300 | $637,800 |
| Income before taxes | −$44.6M | −$41.1M | −$37.9M | −$23.6M | −$19.1M | −$11.8M | −$12.9M | −$8.9M | −$9.9M | −$3.3M |
| Income taxes | — | — | $4.0M | −$3.8M | $1.0M | $825,600 | $681,100 | $170,300 | — | $653,500 |
| Net income | −$44.6M | −$41.1M | −$37.9M | −$23.6M | −$19.1M | −$11.8M | −$12.9M | −$8.9M | −$9.9M | −$3.3M |
| EBITDA | −$39.5M | −$36.7M | −$33.4M | −$20.7M | −$16.6M | −$9.9M | −$11.6M | −$7.9M | −$9.1M | −$2.6M |
| EPS (diluted) | −$0.37 | −$0.39 | −$0.37 | −$0.23 | −$0.20 | −$0.16 | −$0.20 | −$0.21 | −$0.20 | −$0.13 |
| Gross margin | 81.2% | 81.6% | 88.5% | 88.5% | 89.2% | 89.4% | 88.4% | 89.0% | 89.6% | 89.3% |
| Operating margin | −137.1% | −132.5% | −117.0% | −61.8% | −53.7% | −42.3% | −57.4% | −50.5% | −66.4% | −22.2% |
| Net margin | −135.1% | −106.3% | −91.8% | −53.3% | −56.3% | −45.2% | −59.6% | −53.2% | −70.9% | −27.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.3M | $9.7M | $7.3M | $6.8M | $8.5M | $10.4M | $8.7M | $8.2M | $10.4M | $11.3M | $15.7M | $8.0M |
| Cost of revenue | $1.7M | $2.6M | $1.6M | $516,000 | $1.5M | $1.5M | $2.3M | $1.9M | $1.5M | $1.4M | $1.6M | $793,000 |
| Gross profit | $5.6M | $7.1M | $5.7M | $6.3M | $7.0M | $8.9M | $6.4M | $6.2M | $8.9M | $9.9M | $14.1M | $7.2M |
| Research & development | $4.3M | $3.9M | $3.3M | $5.3M | $6.3M | $5.9M | $4.6M | $5.3M | $5.6M | $6.7M | $5.8M | $6.3M |
| Sales, general & admin | $10.6M | $9.4M | $9.0M | $9.9M | $13.9M | $14.2M | $13.7M | $14.0M | $14.3M | $14.5M | $15.3M | $13.9M |
| Total operating expenses | $15.8M | $13.3M | $13.4M | $16.9M | $21.2M | $21.2M | $19.3M | $20.3M | $20.9M | $22.2M | $22.2M | $21.2M |
| Operating income | −$10.2M | −$6.2M | −$7.7M | −$10.6M | −$14.2M | −$12.3M | −$12.9M | −$14.1M | −$12.0M | −$12.3M | −$8.1M | −$14.0M |
| Interest income | $1.4M | $1.4M | $1.6M | $1.7M | $1.9M | $2.0M | $2.3M | $2.5M | $2.6M | $2.7M | $2.8M | $2.7M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $2.3M | — |
| Income before taxes | −$8.9M | −$4.8M | −$9.6M | −$12.4M | −$12.4M | −$10.3M | −$10.6M | −$11.6M | −$9.4M | −$9.5M | −$5.3M | −$11.3M |
| Income taxes | — | — | — | — | — | — | — | — | — | $1.1M | −$1 | $1.90B |
| Net income | −$8.9M | −$4.8M | −$9.6M | −$12.4M | −$12.4M | −$10.3M | −$10.6M | −$11.6M | −$9.4M | −$9.5M | −$5.3M | −$11.3M |
| EBITDA | −$7.7M | −$3.7M | −$8.3M | −$11.1M | −$11.1M | −$9.0M | −$9.1M | −$10.5M | −$8.2M | −$8.3M | −$4.2M | −$12.9M |
| EPS (diluted) | −$0.08 | −$0.04 | −$0.06 | −$0.09 | −$0.12 | −$0.10 | −$0.10 | −$0.11 | −$0.09 | −$0.09 | −$0.05 | −$0.11 |
| Gross margin | 77.0% | 73.2% | 77.9% | 92.4% | 82.1% | 85.6% | 73.8% | 76.4% | 85.7% | 87.6% | 90.0% | 90.1% |
| Operating margin | −140.7% | −64.1% | −105.1% | −154.8% | −167.2% | −118.3% | −148.4% | −172.1% | −114.8% | −108.2% | −51.7% | −174.3% |
| Net margin | −122.0% | −49.2% | −131.5% | −181.8% | −145.3% | −98.8% | −121.9% | −141.6% | −89.9% | −84.0% | −33.7% | −140.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in MXCT's financial statements (latest annual report filed March 25, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
MXCT financial results
In fiscal year 2025 (ended December 31, 2025), MaxCyte reported revenue of $33.0 million, down 14.5% from the year before. It had a net loss of $44.6 million, a net profit margin of −135.1%. Diluted earnings per share came to −$0.37. Over five years revenue grew at an average rate of 4.8% a year.
See the MXCT stock overview for the latest quote and news, or the MXCT chart for price history and technical indicators.
MXCT income statement FAQ
What is MaxCyte's annual revenue?
MaxCyte reported total revenue of $33.0 million for fiscal year 2025, which ended on December 31, 2025. That was down 14.5% from $38.6 million the previous year.
Is MaxCyte profitable?
No. MaxCyte reported a net loss of $44.6 million in fiscal 2025, a net profit margin of −135.1%; its operating margin was −137.1%.
What is MaxCyte's gross margin?
MaxCyte's gross margin was 81.2% in fiscal 2025: for every $100 of revenue, MaxCyte kept $81 after the direct cost of its products and services.
How much does MaxCyte spend on research and development?
MaxCyte spent $20.8 million on research and development in fiscal 2025, 63.1% of revenue.
How fast is MaxCyte growing?
Revenue grew 4.8% a year on average over the last five fiscal years, from $26.2 million to $33.0 million.
What are MaxCyte's earnings per share?
MaxCyte earned $-0.37 per diluted share in fiscal 2025, compared with $-0.39 a year earlier.
When will MaxCyte report its next earnings?
MaxCyte is expected to report results for the quarter ending September 30, 2026 on November 10, 2026 after the market closes.
When does MaxCyte's fiscal year end?
MaxCyte's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 25, 2026.